A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier

Abstract

Breast cancer resistance protein (BCRP) is the most abundant multidrug efflux transporter at the human blood-brain barrier (BBB), restricting brain distribution of various drugs. In this study, we developed a positron emission tomography (PET) protocol to visualize Bcrp function at the murine BBB, based on the dual P-glycoprotein (P-gp)/Bcrp substrate radiotracer 11 Ctariquidar in combination with the Bcrp inhibitor Ko143. To eliminate the contribution of P-gp efflux to 11 Ctariquidar brain distribution, we studied mice in which P-gp was genetically knocked out (Mdr1a/b(-/-) mice) or chemically knocked out by pretreatment with cold tariquidar. We found that 11 Ctariquidar brain uptake increased dose dependently after administration of escalating doses of Ko143, both in Mdr1a/b (-/-) mice and in tariquidar pretreated wild-type mice. After 15 mg/kg Ko143, the maximum increase in 11 Ctariquidar brain uptake relative to baseline scans was 6.3-fold in Mdr1a/b (-/-) mice with a half-maximum effect dose of 4.98 mg/kg and 3.6-fold in tariquidar (8 mg/kg) pretreated wild-type mice, suggesting that the presented protocol is sensitive to visualize a range of different functional Bcrp activities at the murine BBB. We expect that this protocol can be translated to the clinic, because tariquidar can be safely administered to humans at doses that completely inhibit cerebral P-gp. © 2012 ISCBFM All rights reserved.